Conflict of interest statement: Conflict of interest statement G.N. reports 
receiving honoraria from Chugai, Janssen, Yakult Honsha, Taiho, Eli Lilly, 
Miyarinsan and Takeda and research funding to his institution from Eli Lilly, 
outside the submitted work. H.T. reports receiving honoraria from Bayer, 
Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eli Lilly, MBL, Merck Bio Pharma, 
Mitsubishi Tanabe Pharma, MSD, Nippon Kayaku, Novartis, Sanofi, Taiho, Takeda 
and Yakult Honsha and research funding to his institution from Daiichi Sankyo, 
Isofol, MSD, Novartis, Ono, Pfizer, Sumitomo Dainippon Pharma, Sysmex and 
Takeda, outside the submitted work. K.U. reports receiving honoraria from Eli 
Lilly and Chugai, outside the submitted work. K.M. reports receiving honoraria 
from Chugai, outside the submitted work. M.A. reports receiving grant from Kyowa 
Kirin, outside the submitted work. Y.A. reports receiving grants and personal 
fees from Chugai, Kyowa Hakko Kirin, Nippon Kayaku, Yakult Honsha, Mochida, Ono, 
Taiho and Daiichi Sankyo; personal fees from Eli Lilly, Novartis, Bayer, 
Bristol-Myers Squibb, Sawai, Tsumura and Shionogi and grants from Eisai, outside 
the submitted work. K.M. reports receiving grants from Daiichi Sankyo, Parexel 
International, Shionogi Pharma, Sumitomo Dainippon, MSD, Pfizer, Mediscience 
Planning and Solasia Pharma; grants and personal fees from Ono and Sanofi and 
personal fees from Takeda, Taiho, Bristol-Myers Squibb, Bayer, Eli Lilly and 
Chugai, outside the submitted work. Y.K. reports receiving honoraria from Taiho, 
Ono, Daiichi Sankyo, Eli Lilly, Chugai, Yakult Honsha, MSD, Nippon Kayaku, 
Sawai, Tsumura and Miyarinsan and research funding to his institution from 
Taiho, Chugai, Eli Lilly, Sanofi, Nippon Kayaku, Ono, Otsuka, Takeda, MSD and 
Pfizer, outside the submitted work.